睿知中国医院研究地图
候选清单

正在招募胶质瘤III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

5-Aminolevulinic Acid for Photodynamic Diagnosis of Malignant Glioma

ClinicalTrials.gov 上登记的一项胶质瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06160492,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Female participants who are not surgically sterile or who are of childbearing potential must have a negative serum pregnancy test and must not be breastfeeding. Female participants of childbearing potential and male participants whose spouses are of childbearing potential must agree to use contraception for 3 months after study-drug administration.

    入选标准第 12 条

  3. Karnofsky Performance Status (KPS) of at least 60.

    入选标准第 5 条

  4. Hematology: no hematopoietic growth factors, blood transfusions, coagulation-factor transfusions, platelet transfusions, or albumin infusions within 14 days before blood sampling; absolute neutrophil count at least 1.5 x 10\^9/L, platelet count at least 100 x 10\^9/L, and hemoglobin at least 90 g/L.

    入选标准第 8 条

    Liver function: total bilirubin no greater than 1.5 times ULN, or no greater than 3 times ULN in participants with liver metastases from malignant glioma or confirmed Gilbert syndrome; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 2.5 times ULN, or no greater than 5 times ULN in participants with liver metastases from malignant glioma; and serum albumin at least 30 g/L.

    入选标准第 10 条

    Renal function: serum creatinine no greater than 1.5 times ULN, or creatinine clearance at least 50 mL/min calculated using the Cockcroft-Gault formula.

    入选标准第 11 条

  5. Another malignancy within the previous 5 years, except low-grade malignancies treated with curative intent, such as basal-cell carcinoma of the skin, squamous-cell carcinoma of the skin, cervical carcinoma in situ, or papillary thyroid carcinoma.

    排除标准第 7 条

    Active hepatitis B or C, unless antiviral treatment has reduced HBV DNA below the assay's lower detection limit or HCV RNA is negative, as applicable; HIV positivity or a known history of acquired immunodeficiency syndrome.

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06160492,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Male or female participants aged 18 to 75 years, inclusive.
  2. Suspected or confirmed malignant high-grade glioma (WHO grade 3 or 4). The principal investigator must consider the participant suitable for glioma resection, with preoperative assessment indicating that complete tumor resection can be achieved without compromising important physiological functions.
  3. At least one contrast-enhancing lesion on cranial MRI.
  4. Recovery before study-drug administration from prior treatment-related toxicities to grade 1 or less, or to baseline. Alopecia, hyperpigmentation, and chemotherapy-related peripheral neuropathy may be grade 2 or less.
  5. Karnofsky Performance Status (KPS) of at least 60.
  6. Ability to take oral medication.
  7. Laboratory results meeting all of the following criteria:
  8. Hematology: no hematopoietic growth factors, blood transfusions, coagulation-factor transfusions, platelet transfusions, or albumin infusions within 14 days before blood sampling; absolute neutrophil count at least 1.5 x 10\^9/L, platelet count at least 100 x 10\^9/L, and hemoglobin at least 90 g/L.
  9. Coagulation: international normalized ratio (INR) or prothrombin time (PT) no greater than 1.5 times the upper limit of normal (ULN), and activated partial thromboplastin time (APTT) no greater than 1.5 times ULN. Prolongation of INR, PT, or APTT due to anticoagulant treatment may be permitted at the principal investigator's discretion, as excessive bleeding may be controlled by direct pressure.
  10. Liver function: total bilirubin no greater than 1.5 times ULN, or no greater than 3 times ULN in participants with liver metastases from malignant glioma or confirmed Gilbert syndrome; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 2.5 times ULN, or no greater than 5 times ULN in participants with liver metastases from malignant glioma; and serum albumin at least 30 g/L.
  11. Renal function: serum creatinine no greater than 1.5 times ULN, or creatinine clearance at least 50 mL/min calculated using the Cockcroft-Gault formula.
  12. Female participants who are not surgically sterile or who are of childbearing potential must have a negative serum pregnancy test and must not be breastfeeding. Female participants of childbearing potential and male participants whose spouses are of childbearing potential must agree to use contraception for 3 months after study-drug administration.
  13. Ability to understand the informed consent form, voluntary participation with signed informed consent, good compliance, and willingness to cooperate with follow-up.

排除标准:Exclusion Criteria:

  1. Known hypersensitivity to aminolevulinic acid, porphyrins, or structural analogues of either.
  2. Acute or chronic porphyria, photosensitivity, or a history or current diagnosis of photosensitive skin disease.
  3. MRI evidence of a tumor in a critical functional region, such as the basal ganglia, thalamus, cerebellum, or brainstem, where surgery would severely compromise vital functions.
  4. An active infection requiring medication within 2 weeks before study-drug administration, or unexplained fever between screening and dosing accompanied by a markedly elevated procalcitonin level. Participants may be enrolled if the principal investigator determines that the fever is caused by malignant glioma.
  5. A history of major gastrointestinal surgery that may alter drug absorption or activity, such as total gastrectomy or small-intestinal resection, or gastrointestinal dysfunction within the preceding 6 months, including chronic inflammatory bowel disease (such as ulcerative colitis or Crohn's disease), lactose intolerance, malabsorption syndrome, gastrointestinal bleeding, bleeding gastric ulcer, chronic diarrhea, or major surgery for intestinal obstruction or perforation.
  6. Inability to undergo contrast-enhanced MRI, for example because of a pacemaker or contrast-agent allergy.
  7. Another malignancy within the previous 5 years, except low-grade malignancies treated with curative intent, such as basal-cell carcinoma of the skin, squamous-cell carcinoma of the skin, cervical carcinoma in situ, or papillary thyroid carcinoma.
  8. Inadequately controlled cardiovascular disease, including: New York Heart Association (NYHA) functional class II or higher; severe or unstable angina; primary cardiomyopathy; myocardial infarction within 6 months before study-drug administration or a history of coronary or peripheral arterial bypass surgery; hypertension or hypotension judged by the principal investigator to prevent tolerance of surgery and the perioperative period; severe arrhythmia requiring medication and judged by the principal investigator to prevent tolerance of surgery and the perioperative period; or a left ventricular ejection fraction below 50% on screening echocardiography.
  9. Active hepatitis B or C, unless antiviral treatment has reduced HBV DNA below the assay's lower detection limit or HCV RNA is negative, as applicable; HIV positivity or a known history of acquired immunodeficiency syndrome.
  10. Any other condition that, in the principal investigator's judgment, makes participation inappropriate.

引自 ClinicalTrials.gov, NCT06160492, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06160492,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06160492